---
pmid: '32353859'
title: A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
authors:
- Gordon DE
- Jang GM
- Bouhaddou M
- Xu J
- Obernier K
- White KM
- O'Meara MJ
- Rezelj VV
- Guo JZ
- Swaney DL
- Tummino TA
- Hüttenhain R
- Kaake RM
- Richards AL
- Tutuncuoglu B
- Foussard H
- Batra J
- Haas K
- Modak M
- Kim M
- Haas P
- Polacco BJ
- Braberg H
- Fabius JM
- Eckhardt M
- Soucheray M
- Bennett MJ
- Cakir M
- McGregor MJ
- Li Q
- Meyer B
- Roesch F
- Vallet T
- Mac Kain A
- Miorin L
- Moreno E
- Naing ZZC
- Zhou Y
- Peng S
- Shi Y
- Zhang Z
- Shen W
- Kirby IT
- Melnyk JE
- Chorba JS
- Lou K
- Dai SA
- Barrio-Hernandez I
- Memon D
- Hernandez-Armenta C
- Lyu J
- Mathy CJP
- Perica T
- Pilla KB
- Ganesan SJ
- Saltzberg DJ
- Rakesh R
- Liu X
- Rosenthal SB
- Calviello L
- Venkataramanan S
- Liboy-Lugo J
- Lin Y
- Huang XP
- Liu Y
- Wankowicz SA
- Bohn M
- Safari M
- Ugur FS
- Koh C
- Savar NS
- Tran QD
- Shengjuler D
- Fletcher SJ
- O'Neal MC
- Cai Y
- Chang JCJ
- Broadhurst DJ
- Klippsten S
- Sharp PP
- Wenzell NA
- Kuzuoglu-Ozturk D
- Wang HY
- Trenker R
- Young JM
- Cavero DA
- Hiatt J
- Roth TL
- Rathore U
- Subramanian A
- Noack J
- Hubert M
- Stroud RM
- Frankel AD
- Rosenberg OS
- Verba KA
- Agard DA
- Ott M
- Emerman M
- Jura N
- von Zastrow M
- Verdin E
- Ashworth A
- Schwartz O
- d'Enfert C
- Mukherjee S
- Jacobson M
- Malik HS
- Fujimori DG
- Ideker T
- Craik CS
- Floor SN
- Fraser JS
- Gross JD
- Sali A
- Roth BL
- Ruggero D
- Taunton J
- Kortemme T
- Beltrao P
- Vignuzzi M
- García-Sastre A
- Shokat KM
- Shoichet BK
- Krogan NJ
journal: Nature
year: '2020'
full_text_available: false
pmcid: PMC7431030
doi: 10.1038/s41586-020-2286-9
---

# A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
**Authors:** Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, O'Meara MJ, Rezelj VV, Guo JZ, Swaney DL, Tummino TA, Hüttenhain R, Kaake RM, Richards AL, Tutuncuoglu B, Foussard H, Batra J, Haas K, Modak M, Kim M, Haas P, Polacco BJ, Braberg H, Fabius JM, Eckhardt M, Soucheray M, Bennett MJ, Cakir M, McGregor MJ, Li Q, Meyer B, Roesch F, Vallet T, Mac Kain A, Miorin L, Moreno E, Naing ZZC, Zhou Y, Peng S, Shi Y, Zhang Z, Shen W, Kirby IT, Melnyk JE, Chorba JS, Lou K, Dai SA, Barrio-Hernandez I, Memon D, Hernandez-Armenta C, Lyu J, Mathy CJP, Perica T, Pilla KB, Ganesan SJ, Saltzberg DJ, Rakesh R, Liu X, Rosenthal SB, Calviello L, Venkataramanan S, Liboy-Lugo J, Lin Y, Huang XP, Liu Y, Wankowicz SA, Bohn M, Safari M, Ugur FS, Koh C, Savar NS, Tran QD, Shengjuler D, Fletcher SJ, O'Neal MC, Cai Y, Chang JCJ, Broadhurst DJ, Klippsten S, Sharp PP, Wenzell NA, Kuzuoglu-Ozturk D, Wang HY, Trenker R, Young JM, Cavero DA, Hiatt J, Roth TL, Rathore U, Subramanian A, Noack J, Hubert M, Stroud RM, Frankel AD, Rosenberg OS, Verba KA, Agard DA, Ott M, Emerman M, Jura N, von Zastrow M, Verdin E, Ashworth A, Schwartz O, d'Enfert C, Mukherjee S, Jacobson M, Malik HS, Fujimori DG, Ideker T, Craik CS, Floor SN, Fraser JS, Gross JD, Sali A, Roth BL, Ruggero D, Taunton J, Kortemme T, Beltrao P, Vignuzzi M, García-Sastre A, Shokat KM, Shoichet BK, Krogan NJ
**Journal:** Nature (2020)
**DOI:** [10.1038/s41586-020-2286-9](https://doi.org/10.1038/s41586-020-2286-9)
**PMC:** [PMC7431030](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431030/)

## Abstract

1. Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 
Apr 30.

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.

Gordon DE(#)(1)(2)(3)(4), Jang GM(#)(1)(2)(3)(4), Bouhaddou M(#)(1)(2)(3)(4), Xu 
J(#)(1)(2)(3)(4), Obernier K(#)(1)(2)(3)(4), White KM(#)(5)(6), O'Meara 
MJ(#)(7), Rezelj VV(#)(8), Guo JZ(1)(2)(3)(4), Swaney DL(1)(2)(3)(4), Tummino 
TA(1)(2)(9), Hüttenhain R(1)(2)(3)(4), Kaake RM(1)(2)(3)(4), Richards 
AL(1)(2)(3)(4), Tutuncuoglu B(1)(2)(3)(4), Foussard H(1)(2)(3)(4), Batra 
J(1)(2)(3)(4), Haas K(1)(2)(3)(4), Modak M(1)(2)(3)(4), Kim M(1)(2)(3)(4), Haas 
P(1)(2)(3)(4), Polacco BJ(1)(2)(3)(4), Braberg H(1)(2)(3)(4), Fabius 
JM(1)(2)(3)(4), Eckhardt M(1)(2)(3)(4), Soucheray M(1)(2)(3)(4), Bennett 
MJ(1)(2)(3)(4), Cakir M(1)(2)(3)(4), McGregor MJ(1)(2)(3)(4), Li Q(1)(2)(3)(4), 
Meyer B(8), Roesch F(8), Vallet T(8), Mac Kain A(8), Miorin L(5)(6), Moreno 
E(5)(6), Naing ZZC(1)(2)(3)(4), Zhou Y(1)(2)(3)(4), Peng S(1)(2)(9), Shi 
Y(1)(2)(4)(10), Zhang Z(1)(2)(4)(10), Shen W(1)(2)(4)(10), Kirby 
IT(1)(2)(4)(10), Melnyk JE(1)(2)(4)(10), Chorba JS(1)(2)(4)(10), Lou 
K(1)(2)(4)(10), Dai SA(1)(2)(4)(10), Barrio-Hernandez I(11), Memon D(11), 
Hernandez-Armenta C(11), Lyu J(1)(2)(9), Mathy CJP(1)(2)(12)(13), Perica 
T(1)(2)(12), Pilla KB(1)(2)(12), Ganesan SJ(1)(2)(12), Saltzberg DJ(1)(2)(12), 
Rakesh R(1)(2)(12), Liu X(1)(2)(9), Rosenthal SB(14), Calviello L(1)(15), 
Venkataramanan S(1)(15), Liboy-Lugo J(1)(15), Lin Y(1)(15), Huang XP(16), Liu 
Y(16), Wankowicz SA(1)(2)(12)(17), Bohn M(1)(2)(9), Safari M(1)(2)(18), Ugur 
FS(1)(2)(4)(9), Koh C(8), Savar NS(8), Tran QD(8), Shengjuler D(8), Fletcher 
SJ(8), O'Neal MC(19), Cai Y(19), Chang JCJ(19), Broadhurst DJ(19), Klippsten 
S(19), Sharp PP(4), Wenzell NA(1)(2)(4), Kuzuoglu-Ozturk D(1)(20)(21), Wang 
HY(1)(2)(4), Trenker R(1)(2)(22), Young JM(23), Cavero DA(1)(3)(24), Hiatt 
J(1)(3)(25), Roth TL(1)(3)(24)(25), Rathore U(1)(3)(24), Subramanian 
A(1)(2)(24), Noack J(1)(2)(24), Hubert M(26), Stroud RM(1)(2)(18), Frankel 
AD(1)(2)(18), Rosenberg OS(1)(2)(18)(27), Verba KA(1)(2)(9), Agard DA(1)(2)(18), 
Ott M(1)(2)(3)(27), Emerman M(28), Jura N(1)(2)(4)(22), von Zastrow 
M(1)(2)(4)(29), Verdin E(1)(27)(30), Ashworth A(1)(2)(20), Schwartz O(26), 
d'Enfert C(31), Mukherjee S(1)(2)(24), Jacobson M(1)(2)(9), Malik HS(23), 
Fujimori DG(1)(2)(4)(9), Ideker T(1)(32), Craik CS(1)(2)(9)(20), Floor 
SN(1)(15)(20), Fraser JS(1)(2)(12), Gross JD(1)(2)(9), Sali A(1)(2)(9)(12), Roth 
BL(16), Ruggero D(1)(2)(4)(20)(21), Taunton J(1)(2)(4), Kortemme 
T(1)(2)(12)(13), Beltrao P(1)(11), Vignuzzi M(33), García-Sastre 
A(34)(35)(36)(37), Shokat KM(38)(39)(40)(41), Shoichet BK(42)(43)(44), Krogan 
NJ(45)(46)(47)(48)(49).

Author information:
(1)QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
(2)Quantitative Biosciences Institute (QBI), University of California San 
Francisco, San Francisco, CA, USA.
(3)J. David Gladstone Institutes, San Francisco, CA, USA.
(4)Department of Cellular and Molecular Pharmacology, University of California 
San Francisco, San Francisco, CA, USA.
(5)Department of Microbiology, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA.
(6)Global Health and Emerging Pathogens Institute, Icahn School of Medicine at 
Mount Sinai, New York, NY, USA.
(7)Department of Computational Medicine and Bioinformatics, University of 
Michigan, Ann Arbor, MI, USA.
(8)Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 
Paris, France.
(9)Department of Pharmaceutical Chemistry, University of California San 
Francisco, San Francisco, CA, USA.
(10)Howard Hughes Medical Institute, University of California San Francisco, San 
Francisco, CA, USA.
(11)European Molecular Biology Laboratory (EMBL), European Bioinformatics 
Institute, Wellcome Genome Campus, Cambridge, UK.
(12)Department of Bioengineering and Therapeutic Sciences, University of 
California San Francisco, San Francisco, CA, USA.
(13)The UC Berkeley-UCSF Graduate Program in Bioengineering, University of 
California San Francisco, San Francisco, CA, USA.
(14)Center for Computational Biology and Bioinformatics, Department of Medicine, 
University of California San Diego, San Diego, CA, USA.
(15)Department of Cell and Tissue Biology, University of California San 
Francisco, San Francisco, CA, USA.
(16)Department of Pharmacology, University of North Carolina at Chapel Hill 
School of Medicine, Chapel Hill, NC, USA.
(17)Biophysics Graduate Program, University of California San Francisco, San 
Francisco, CA, USA.
(18)Department of Biochemistry and Biophysics, University of California San 
Francisco, San Francisco, CA, USA.
(19)Zoic Labs, Culver City, CA, USA.
(20)Helen Diller Family Comprehensive Cancer Center, University of California 
San Francisco, San Francisco, CA, USA.
(21)Department of Urology, University of California San Francisco, San 
Francisco, CA, USA.
(22)Cardiovascular Research Institute, University of California San Francisco, 
San Francisco, CA, USA.
(23)Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, 
WA, USA.
(24)George William Hooper Foundation, Department of Microbiology and Immunology, 
University of California San Francisco, San Francisco, CA, USA.
(25)Medical Scientist Training Program, University of California San Francisco, 
San Francisco, CA, USA.
(26)Virus and Immunity Unit, Institut Pasteur, Paris, France.
(27)Department of Medicine, University of California San Francisco, San 
Francisco, CA, USA.
(28)Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, 
WA, USA.
(29)Department of Psychiatry, University of California San Francisco, San 
Francisco, CA, USA.
(30)Buck Institute for Research on Aging, Novato, CA, USA.
(31)Direction Scientifique, Institut Pasteur, Paris, France.
(32)Division of Genetics, Department of Medicine, University of California San 
Diego, San Diego, CA, USA.
(33)Viral Populations and Pathogenesis Unit, CNRS UMR 3569, Institut Pasteur, 
Paris, France. marco.vignuzzi@pasteur.fr.
(34)Department of Microbiology, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
(35)Global Health and Emerging Pathogens Institute, Icahn School of Medicine at 
Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
(36)Department of Medicine, Division of Infectious Diseases, Icahn School of 
Medicine at Mount Sinai, New York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
(37)The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA. Adolfo.Garcia-Sastre@mssm.edu.
(38)QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. 
Kevan.Shokat@ucsf.edu.
(39)Quantitative Biosciences Institute (QBI), University of California San 
Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
(40)Department of Cellular and Molecular Pharmacology, University of California 
San Francisco, San Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
(41)Howard Hughes Medical Institute, University of California San Francisco, San 
Francisco, CA, USA. Kevan.Shokat@ucsf.edu.
(42)QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. 
shoichet@cgl.ucsf.edu.
(43)Quantitative Biosciences Institute (QBI), University of California San 
Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu.
(44)Department of Pharmaceutical Chemistry, University of California San 
Francisco, San Francisco, CA, USA. shoichet@cgl.ucsf.edu.
(45)QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA. 
nevan.krogan@ucsf.edu.
(46)Quantitative Biosciences Institute (QBI), University of California San 
Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
(47)J. David Gladstone Institutes, San Francisco, CA, USA. 
nevan.krogan@ucsf.edu.
(48)Department of Cellular and Molecular Pharmacology, University of California 
San Francisco, San Francisco, CA, USA. nevan.krogan@ucsf.edu.
(49)Department of Microbiology, Icahn School of Medicine at Mount Sinai, New 
York, NY, USA. nevan.krogan@ucsf.edu.
(#)Contributed equally

Comment in
    Nat Rev Immunol. 2020 Jun;20(6):351. doi: 10.1038/s41577-020-0318-1.
    Psychiatry Res. 2021 Jan;295:113626. doi: 10.1016/j.psychres.2020.113626.
    Schizophr Res. 2022 Mar;241:140-141. doi: 10.1016/j.schres.2022.01.035.

Update of
    bioRxiv. 2020 Mar 27:2020.03.22.002386. doi: 10.1101/2020.03.22.002386.

A newly described coronavirus named severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus 
disease 2019 (COVID-19), has infected over 2.3 million people, led to the death 
of more than 160,000 individuals and caused worldwide social and economic 
disruption1,2. There are no antiviral drugs with proven clinical efficacy for 
the treatment of COVID-19, nor are there any vaccines that prevent infection 
with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the 
limited knowledge of the molecular details of how SARS-CoV-2 infects cells. Here 
we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells 
and identified the human proteins that physically associated with each of the 
SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 
332 high-confidence protein-protein interactions between SARS-CoV-2 and human 
proteins. Among these, we identify 66 druggable human proteins or host factors 
targeted by 69 compounds (of which, 29 drugs are approved by the US Food and 
Drug Administration, 12 are in clinical trials and 28 are preclinical 
compounds). We screened a subset of these in multiple viral assays and found two 
sets of pharmacological agents that displayed antiviral activity: inhibitors of 
mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors. 
Further studies of these host-factor-targeting agents, including their 
combination with drugs that directly target viral enzymes, could lead to a 
therapeutic regimen to treat COVID-19.

DOI: 10.1038/s41586-020-2286-9
PMCID: PMC7431030
PMID: 32353859 [Indexed for MEDLINE]
